A Case of Intestinal Behcet's Disease Treated with Infliximab Monotherapy Who Successfully Maintained Clinical Remission and Complete Mucosal Healing for Six Years
A Case of Intestinal Behcet's Disease Treated with Infliximab Monotherapy Who Successfully Maintained Clinical Remission and Complete Mucosal Healing for Six Years
复制标题
DOI：
10.2169/internalmedicine.51.8005
复制
发表时间：
2012-01-01
影响因子：
1.2
通讯作者：
Hibi, Toshifumi
中科院分区：
文献类型：
--
作者：
Maruyama, Yuriko;Hisamatsu, Tadakazu;Hibi, Toshifumi
白塞氏病是一种慢性复发性疾病，累及多个器官系统，包括胃肠道，称为肠道白塞氏病。肠白塞氏病通常对经验性治疗如5-氨基水杨酸、免疫调节剂和类固醇具有抗性，并且通常导致穿孔，需要手术切除。因此，肠道病变被认为是白塞病的一个不良预后因素。最近，多份报告证实了抗TNF α单克隆抗体（例如英夫利西单抗）对肠道白塞病的疗效，但抗TNF α治疗是否能改善肠道白塞病患者的预后仍不清楚。我们在此报告的情况下，一个成年女性患者与肠道白塞氏病谁反应良好的诱导治疗与英夫利昔单抗，并已维持在缓解计划管理英夫利昔单抗。她的C反应蛋白水平一直保持在阴性水平，内镜检查结果显示粘膜完全愈合。因此，英夫利西单抗可能有可能诱导肠白塞病患者的“持续深度缓解”。
Behcet's disease is a chronic relapsing disease with multiple organ system involvement, including the gastrointestinal tract, which is known as intestinal Behcet's disease. Intestinal Behcet's disease is often resistant to empirical treatments such as 5-aminosalicylic acid, immunomodulators and steroids and often causes a perforation, requiring surgical resection. Therefore, intestinal lesions are considered to be a poor prognostic factor in Behcet's disease. Recently, several reports have demonstrated the efficacy of anti-TNF alpha monoclonal antibodies, such as infliximab, against intestinal Behcet's disease, however, it remains unknown whether anti-TNF alpha therapy can improve the prognosis of patients with intestinal Behcet's disease. We herein report the case of an adult female patient with intestinal Behcet's disease who responded well to the induction therapy with infliximab, and has been maintained in remission by scheduled administration of infliximab. Her C-reactive protein level has been sustained at a negative level, and endoscopic findings revealed complete mucosal healing. Therefore, infliximab may have the potential to induce "sustained deep remission" in patients with intestinal Behcet's disease.